MARSHALL WACE, LLP

Position in VKTX — Viking Therapeutics, Inc.

CIK 1318757 LONDON, X0

Position in VKTX

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$2,940,314

-$2,079,818 QoQ

Shares Held

90,360

-56.5% QoQ

Ownership

0.078%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2022

12 quarters on record

Voting authority Sole 0.ToString("F0")% Shared 100.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

MARSHALL WACE, LLP holds $2,766,756,129 across 280 Biotechnology names. VKTX ranks #135 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	1,099,318	$363,731,344
2	VRTX	Vertex Pharmaceuticals Inc / Ma	317,058	$141,579,078
3	INCY	Incyte Corp	1,253,138	$117,945,347
4	RPRX	Royalty Pharma plc	2,120,692	$101,729,594
5	RCUS	Arcus Biosciences, Inc.	3,761,437	$81,247,039
6	PTGX	Protagonist Therapeutics, Inc	628,075	$66,199,104
7	ROIV	Roivant Sciences Ltd.	2,246,943	$62,240,320
8	COGT	Cogent Biosciences, Inc.	1,600,168	$61,590,466

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$2,940,314	90,360	-56.5%	Shares	Other	2026-05-15
2025-03-31	$5,020,132	207,873	+933.5%	Shares	Other	2025-05-15
2024-12-31	$809,387	20,114	+12.6%	Shares	Other	2025-02-13
2024-09-30	$1,130,589	17,858	-75.8%	Shares	Other	2024-11-14
2024-06-30	$3,906,837	73,700	-80.2%	Shares	Other	2024-08-14
2024-03-31	$30,478,252	371,686	+261.4%	Shares	Other	2024-05-15
2023-12-31	$1,914,131	102,855	+95.7%	Shares	Other	2024-02-14
2023-09-30	$581,817	52,558	-60.5%	Shares	Other	2023-11-14
2023-06-30	$2,159,009	133,190	+57.2%	Shares	Other	2023-08-14
2023-03-31	$1,410,637	84,723	+20.5%	Shares	Other	2023-05-15
2022-12-31	$661,149	70,335	-94.7%	Shares	Other	2023-02-14
2022-09-30	$3,637,673	1,337,380	—	Shares	Other	2022-11-14
No filing history on record for this holder in this stock.